National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans

Journal of Medical Economics

Volumn 17, Issue 1, 2014, Pages 1-10

  Joyce, Amie T ^a   Gandra, Shravanthi R ^b   Fox, Kathleen M ^c   Smith, Timothy W ^a   Pill, Michael W ^d  

^a IQVIA   (United States)

^b AMGEN INC   (United States)

^c Strategic Healthcare Solutions LLC   (United States)

^d Gemini Healthcare LLC   (United States)

Author keywords

Costs; Dose escalation; Regional estimates; Rheumatoid arthritis; Tumor necrosis factor blocker

Indexed keywords

ADALIMUMAB; ANALGESIC AGENT; ETANERCEPT; GLUCOCORTICOID; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAID; MIDDLE AGED; OUTCOME ASSESSMENT; PHARMACEUTICAL CARE; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; UNITED STATES;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES; YOUNG ADULT;

EID: 84890468040     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.856314     Document Type: Article

References (36)

1. Ritchlin CT. Mechanisms of erosion in rheumatoid arthritis. J Rheumatol 2004;31:1229-37
2. Cook AD, Visvanathan K. Molecular targets in immune-mediated diseases: focus on rheumatoid arthritis. Expert Opin Therap Targets 2004;8:375-90
3. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376: 1094-108
4. Kalyoncu U, Dougados M, Daures JP, et al. Reporting of patient-reported outcomes in recent trials in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2009;68:183-90
5. Isik A, Koca SS, Ozturk A, et al. Anxiety and depression in patients with rheumatoid arthritis. Clin Rheumatol 2007;26:872-8
6. Sheehy C, Murphy E, Barry M. Depression in rheumatoid arthritis - underscoring the problem. Rheumatology (Oxford) 2006;45:1325-7
7. Yelin E. Work disability in rheumatic diseases. Curr Opin Rheumatol 2007;19:91-6
8. Birnbaum H, Pike C, Kaufman R, et al. Societal cost of rheumatoid arthritis patients in the US. Curr Med Res Opin 2010;26:77-90
9. Sullivan PW, Ghushchyan V, Huang XY, et al. Influence of rheumatoid arthritis on employment, function, and productivity in a nationally representative sample in the United States. J Rheumatol 2010;37:544-9
10. Breedveld FC, Weisman MH, Kavanaugh AF, et al. A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patient with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37
11. Breedveld F, Emery P, Ferraccioli G, et al. Clinical response and remission at 12, 24, and 52 weeks with the combination of etanercept and methotrexate in the treatment of early active rheumatoid arthritis in the COMET trial. Ann Rheum Dis 2008;67(2 Suppl):1
12. Van der Heijde D, Klareskog L, Landewe R, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:3928-39
13. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomized, double-blind, parallel treatment trial. Lancet 2008;372:375-82
14. HUMIRA (adalimumab) PI, 03/2011. Abbott Laboratories
15. REMICADE (infliximab) PI, 04/2011. Centocor Ortho Biotech Inc
16. ENBREL (etanercept) PI, 05/2011. Manufactured by Immunex Corporation. Marketed by Amgen Inc. and Pfizer Inc.
17. Gu NY, Huang XY, Fox KM, et al. Claims data analysis of dosing and cost of TNF antagonists. Am J Pharm Benef 2010;2:351-9
18. Harrison DJ, Huang X, Globe D. Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis. Am J Health-Syst Pharm 2010;67:1281-7
19. Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and meta-analysis of efficacy and safety. BMC Musculoskel Disord 2008;9:52
20. Zintzaras E, Dahabreh IJ, Giannouli S, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens. Clin Therap 2008;30:1939-55
21. Perdriger A. Infliximab in the treatment of rheumatoid arthritis. Biologics 2009;3:183-91
22. Moots RJ, Haraoui B, Matucci-Cerinic M, et al. Differences in biologic doseescalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice. Clin Exper Rheumatol 2011;29:26-34
23. Gilbert TD, Smith D, Ollendorf DA. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskel Disord 2004;5:36
24. Bullano MF, McNeeley BJ, Yu YF, et al. Comparison of costs associated with the use of etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritis. Manag Care Interf 2006;19:47-53
25. Wu E, Chen L, Birnbaum H, et al. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis. Curr Med Res Opin 2008;24:2229-40
26. Ollendorf DA, Klingman D, Hazard E, et al. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Clin Therap 2009;31:825-35
27. Huang X, Gu NY, Fox KM, et al. Comparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practice. Curr Med Res Opin 2010;26: 1637-45
28. Flood J, Mihalik C, Fleming RR, et al. The use of therapeutic interchange for biologic therapies. Managed Care 2007;16:51-62
29. Ogden CL, Fryar CD, Carroll MD, et al. Mean body weight, height, and body mass index, United States 1960-2002. Vital Health Stat 2004;347:1-17
30. First DataBank. AnalySource Online. Wholesale Acquisition Cost (WAC). http://www.fdbhealth.com/fdb-medknowledge-drug-pricing. Accessed September 11, 2012
31. Bonafede MK, Gandra SR, Fox KM, et al. Tumor necrosis factor-blocker dose escalation among biologic näve rheumatoid arthritis patients in commercial managed care plans in the two years following therapy initiation. J Med Econ 2012;15:1-9
32. Khanna D, Cyhaniuk A, Bedenbaugh A. Use of TNF inhibitors in the US: Utilisation patterns and dose escalation from a retrospective US RA population [abstract]. Ann Rheum Dis 2011;70(3 Suppl):197
33. Blom M, Kievit W, Kuper HH, et al. Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice. Arthritis Care Res 2010;62:1335-41
34. Schabert VF, Bruce B, Ferrufino CF, et al. Disability outcomes and dose escalation in rheumatoid arthritis patients treated with tumor necrosis factor blockers: a comparative effectiveness analysis [abstract PMS2]. Value Health 2010;13:A302
35. Segal SD, Power DJ, Smith DB, et al. Comparative effectiveness analysis of TNF blockers in rheumatoid arthritis (RA) patients in US community practice [abstract]. Ann Rheum Dis 2011;70(3 Suppl):252
36. Etemad L, Yu EB, Wanke LA. Dose adjustment over time of etanercept and infliximab in patients with rheumatoid arthritis. Manag Care Interf 2005;18:21-7